Examining the effect of mitochondrial oxidative stress in DCM
Examining the role of mitochondrial oxidative stress in dilated cardiomyopathy
Imperial College London
Duration of Study in the UK
3 years, 6 months, 1 days
Dilated cardiomyopathy is a common disease of the heart muscle, where the heart becomes stretched and the pumping chambers become weak. This can lead to heart failure which occurs whenever the heart is unable to pump enough blood around the body. Many patients die from heart failure within 5 years. New treatments are needed. In dilated cardiomyopathy, there are abnormalities in how heart cells make energy. Reduced energy production contributes to the weakness of the heart and the development of heart failure.
We will investigate if we may be able to promote recovery by improving the function of mitochondria. MitoQ is a health supplement that is thought to improve the energy supply by protecting the energy producing centres inside heart cells, called mitochondria, from damage. We will, therefore, investigate whether improving mitochondrial function leads to recovery in heart function amongst patients with dilated cardiomyopathy. We will do this by studying 106 patients and giving half MitoQ and half a placebo (a tablet without any medication in it) for 1 year. Neither group will know which treatment they are taking. We will compare the symptoms and the heart function of the groups after 1 year.
The study will take place at Royal Brompton Hospital and Imperial College London. Funding is provided by the British Heart Foundation. Participants will attend 3 study visits, each taking between 1-3 hours. They will have 2-3 MRI scans and on each visit have an electrocardiogram recorded, blood samples taken and stored, complete a symptoms questionnaires and do a 6 minute walking test.
London - Surrey Research Ethics Committee
Date of REC Opinion
4 Jun 2021
Further Information Favourable Opinion